Why the study?
The feasibility of using real-world data to evaluate the safety and effectiveness of cardiac ablation catheters for persistent AF and ischaemic VT was unknown.
Is it feasible to use real-world data to evaluate the safety and effectiveness of cardiac ablation catheters compared to manual chart validation?
Is it feasible to use real-world data to evaluate the safety and effectiveness of cardiac ablation catheters compared to manual chart validation?
Real-world data can feasibly identify safety and effectiveness outcomes for cardiac ablation catheters, though positive predictive values vary significantly depending on the specific clinical endpoint.
RWD accuracy varies by endpoint and warrants caution for stroke or arrhythmia outcomes; leaves open standardized use in ablation studies pending further validation.
OBJECTIVES: To determine the feasibility of using real-world data to assess the safety and effectiveness of two cardiac ablation catheters for the treatment of persistent atrial fibrillation and ischaemic ventricular tachycardia. DESIGN: Retrospective cohort. SETTING: Three health systems in the USA. PARTICIPANTS: Patients receiving ablation with the two ablation catheters of interest at any of the three health systems. MAIN OUTCOME MEASURES: Feasibility of identifying the medical devices and participant populations of interest as well as the duration of follow-up and positive predictive values (PPVs) for serious safety (ischaemic stroke, acute heart failure and cardiac tamponade) and effectiveness (arrhythmia-related hospitalisation) clinical outcomes of interest compared with manual chart validation by clinicians. RESULTS: Overall, the catheter of interest for treatment of persistent atrial fibrillation was used for 4280 ablations and the catheter of interest for ischaemic ventricular tachycardia was used 1516 times across the data available within the three health systems. The duration of patient follow-up in the three health systems ranged from 91% to 97% at ≥7 days, 89% to 96% at ≥30 days, 77% to 90% at ≥6 months and 66% to 84% at ≥1 year. PPVs were 63.4% for ischaemic stroke, 96.4% for acute heart failure, 100% at one health system for cardiac tamponade and 55.7% for arrhythmia-related hospitalisation. CONCLUSIONS: It is feasible to use real-world health system data to evaluate the safety and effectiveness of cardiac ablation catheters, though evaluations must consider the implications of variation in follow-up and endpoint ascertainment among health systems.
No takes yet. Share an insight, caveat, or question.
Dhruva et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: